Dominant Frequency Mapping as a Functional Tool for Substrate‐Guided Ventricular Tachycardia Ablation Authors: Selim M Zor, Wiert Hoeksema, Bart Baselmans, Michiel J B Kemme, Pieter G Postema, Pranav Bhagirath Published: 2026 ABSTRACT ABSTRACTIntroductionAccurate identification of arrhythmogenic substrate is essential for successful ventricular tachycardia (VT) ablation, yet existing electrogram‐based methods are limited by far‐field interference and operator dependence. Dominant frequency (DF) mapping offers a stimulus‐independent alternative, but existing implementations lack anatomically integrated workflows with quantitative assessment of spatial concordance.MethodsThe objective of this study is to develop and evaluate a computational workflow for DF mapping with three‐dimensional anatomical integration in patients undergoing substrate‐guided VT ablation. We retrospectively analyzed 12 patients (mean age 57.5 ± 18.0 years; 75% male) with ischemic or non‐ischemic cardiomyopathy. Intracardiac electrograms from SmartTouch or Pentaray catheters were segmented, transformed into the frequency domain, and thresholded using case‐specific histograms. DF activity was projected onto patient‐specific ventricular meshes, and spatial correspondence with operator‐defined ablation sites was quantified using continuous proximity metrics (soft recall, soft precision) and receiver operating characteristic (ROC) analysis.ResultsDF analysis was successful in all cases, with projection errors < 4 mm. DF activity showed high soft recall (0.776–0.999) and variable soft precision (0.025–0.754). ROC AUC values ranged from 0.622 to 0.953, exceeding baseline in all cases. SmartTouch data generally yielded higher recall and greater separation between ablation and non‐ablation points.ConclusionDF mapping with anatomical integration is feasible across catheter types and demonstrates consistent spatial concordance with operator‐defined VT ablation targets. This stimulus‐independent workflow can be applied to routine mapping data and provides a framework for quantitative assessment of spatial relationships with procedural targets. DF values were case‐specific and not comparable across patients, catheter types, or institutions. Prospective evaluation in larger cohorts is warranted.Keywords: catheter ablation, dominant frequency, functional substrate mapping, peak frequency, ventricular tachycardia Introduction Catheter ablation is a cornerstone of therapy for sustained ventricular tachycardia (VT) in patients with structural heart disease. Accurate identification of arrhythmogenic substrate is essential to procedural success, yet recurrence rates of 30%–50% are still reported even in experienced centers [1]. Electrogram‐based approaches such as bipolar voltage mapping, late potential (LP) detection, and identification of local abnormal ventricular activity (LAVAs) remain limited by far‐field interference, catheter orientation, and signal attenuation [2]. Visual annotation is time‐consuming and operator‐dependent, which reduces reproducibility. To overcome these limitations, interest has shifted toward functional mapping techniques that provide objective, physiology‐based metrics from intracardiac electrograms (IEGMs). Decrement‐evoked potential (DEEP) and evoked delayed potential (EDP) mapping are among the most widely studied approaches [3, 4]. These methods identify sites where electrograms show stimulus‐QRS delay or decrement during programmed stimulation, which reflects slow conduction within the VT circuit. Early studies suggest that DEEP or EDP‐guided ablation can improve procedural specificity by targeting functionally critical channels within low‐voltage areas [5]. However, they require multiple pacing protocols, may be influenced by cycle length and pacing site, and depend on patient haemodynamic stability. Their reliance on stimulation‐induced responses also limits use in patients who cannot tolerate pacing or when arrhythmia induction is avoided. Frequency‐domain analysis of sinus or paced rhythm electrograms offers a stimulus‐independent alternative for probing local conduction properties. Dominant frequency (DF) mapping can be performed rapidly on data acquired during routine mapping and provides a quantitative marker that may highlight both superficial and deep intramural substrate. High‐frequency activity has been linked to midmyocardial fibrosis and other arrhythmogenic regions that may not be apparent on voltage maps [6]. Most previous studies have used offline or partially manual analysis, two‐dimensional visualization and binary lesion overlap, with limited anatomical integration and no standardized method for spatial concordance assessment. DF analysis could be combined with DEEP or EDP mapping to integrate complementary physiological information: temporal delay from pacing and spectral content from intrinsic signals. Several developments make DF mapping timely. High‐density mapping catheters are now in routine use, computational analysis can be performed in real time in the electrophysiology laboratory, and there is increasing emphasis on advanced analysis tools that can be applied during sinus rhythm or stable pacing. Despite this, no established pipeline exists for DF extraction, projection onto patient‐specific three‐dimensional ventricular models, and quantitative assessment against ablation targets. In this study, we developed a DF mapping workflow that includes IEGM segmentation, spectral analysis, and three‐dimensional anatomical projection. We applied it retrospectively in patients undergoing VT ablation and evaluated feasibility, applicability with different catheter types, and spatial performance using continuous proximity metrics and discriminative analysis. This represents a first step toward quantitative, spatially resolved assessment of DF activity in relation to procedural ablation targets, providing a foundation for future clinical validation. Methods Study Population We retrospectively analyzed patients with sustained VT who underwent catheter ablation at Amsterdam University Medical Centers. VT diagnosis was confirmed from clinical records and 12‐lead electrocardiography. Both ischemic and non‐ischemic cardiomyopathy were included. Patients with prior cardiac surgery, additional arrhythmias (e.g., atrial fibrillation), or incomplete intracardiac electrogram (IEGM) data were excluded. The study was approved by the institutional ethics committee, and all patients had provided written informed consent for the use of their data for research purposes. Data Acquisition Electrograms were acquired with the CARTO 3 mapping system (Biosense Webster, Irvine, CA, USA) using either an irrigated‐tip contact force catheter (SmartTouch) or a multielectrode mapping catheter (Pentaray), or both, enabling evaluation of the method's performance across differing electrode sizes, interelectrode spacing, and signal bandwidths. Mapping was performed during sinus rhythm and/or right ventricular pacing according to clinical protocol. Data exports included bipolar IEGMs, surface ECGs, three‐dimensional (3D) catheter point coordinates, and patient‐specific ventricular geometries. Dominant Frequency Analysis A computational analysis pipeline was developed to extract and spatially map DF activity. 1.Signal segmentation: A region of interest (ROI) was defined around the R wave in lead V2 to account for variability in QRS onset and morphology (Figure 1A). Pre‐ and post‐peak offsets from the R wave were applied uniformly to all mapping channels to standardize temporal alignment (Figure 1B). Lead V2 served solely as a temporal reference. Recordings without a detected surface QRS peak were excluded. Signal segmentation: A region of interest (ROI) was defined around the R wave in lead V2 to account for variability in QRS onset and morphology (Figure 1A). Pre‐ and post‐peak offsets from the R wave were applied uniformly to all mapping channels to standardize temporal alignment (Figure 1B). Lead V2 served solely as a temporal reference. Recordings without a detected surface QRS peak were excluded. 2.Spectral analysis: Segmented electrograms were transformed into the frequency domain using the fast Fourier transform (Figure 1B3). The peak frequency (PF) was defined as the frequency with the maximum spectral magnitude, rounded to the nearest Hz. PF was chosen as a pragmatic and computationally efficient descriptor for three‐dimensional integration. Spectral analysis: Segmented electrograms were transformed into the frequency domain using the fast Fourier transform (Figure 1B3). The peak frequency (PF) was defined as the frequency with the maximum spectral magnitude, rounded to the nearest Hz. PF was chosen as a pragmatic and computationally efficient descriptor for three‐dimensional integration. 3.Threshold definition: A histogram of PF values was generated for each case, and the DF threshold was selected by visual identification of the inflection point of the PF distribution and was applied uniformly within each case without any additional tuning. Electrogram sites with PF values above this threshold were classified as containing DF activity (Figure 1C). Threshold definition: A histogram of PF values was generated for each case, and the DF threshold was selected by visual identification of the inflection point of the PF distribution and was applied uniformly within each case without any additional tuning. Electrogram sites with PF values above this threshold were classified as containing DF activity (Figure 1C). Signal variability, segmentation process, and DF threshold selection. Example from Case 1 showing the DF analysis workflow. Blue panel (A) Lead V2 recordings (files 1, 100, 200) display marked variability in morphology and QRS onset, motivating standardized segmentation around the R‐wave. Red panel depicts signals from the SmartTouch catheter, ROI was defined around the R‐peak (B, top and middle row ‐ red dashed line), bounded by vertical blue lines with pre‐/post‐peak segments shaded in light blue and orange. Mapping lead segments from this ROI (gray) were transformed via FFT, yielding a PF of 42 Hz (B, bottom row). A PF histogram was then used to select the DF threshold (here 40 Hz), defined at the histogram's inflection point; recordings above this threshold were classified as containing DF activity, green panel (C). Anatomical Data Processing Patient‐specific ventricular meshes were generated from electroanatomic mapping data and processed in 3D Slicer (v5.8.1). Ablation sites were projected onto the nearest mesh surface, and projection distances were recorded for quality control. DF values above the threshold were interpolated over the ventricular surface using inverse‐distance weighting, and sites below the threshold were excluded from interpolation. Color maps were generated to visualize DF distribution, with ablation sites overlaid for qualitative comparison (Figure 2). Effect of DF threshold on spatial distribution of DF activity. For Case 6, DF maps were rendered on the left ventricular mesh using thresholds of 0, 80, and 160 Hz, as captured with the SmartTouch catheter. Increasing the threshold reduced the spatial extent of DF regions. Projected ablation sites are overlaid as white dots. Maps were generated using inverse‐distance interpolation of PF values above the selected threshold. Spatial Concordance Analysis Spatial correspondence between DF activity and ablation targets was quantified using continuous proximity scores derived from the Euclidean distance between DF points and ablation sites, transformed with a Gaussian kernel (standard deviation 5 mm, approximating clinical lesion size) [7, 8, 9]. Ablation sites were used as a procedural reference reflecting operator‐defined targeting rather than definitive functional VT circuit components. Two primary metrics were computed: Soft recall: mean proximity score at ablation sites, reflecting the proportion of lesions located near DF activity. Soft recall: mean proximity score at ablation sites, reflecting the proportion of lesions located near DF activity. Soft precision: mean proximity score at DF points, reflecting the proportion of DF activity near ablation sites. Soft precision: mean proximity score at DF points, reflecting the proportion of DF activity near ablation sites. To assess discriminative performance, proximity scores were used to classify mesh vertices as ablation or non‐ablation points, generating receiver operating characteristic (ROC) and precision‐recall (PR) curves. The area under the ROC curve (AUC) and average precision (AP) were calculated. Statistical Analysis Statistical analysis was performed in Python (v3.10) using SciPy and scikit‐learn. Proximity scores at ablation and non‐ablation sites were compared using the Mann–Whitney U test with Bonferroni correction. Each case was treated as an independent comparison, with cases including both SmartTouch and Pentaray recordings contributing two comparisons (18 total; p < 0.0028). Overall classification performance was assessed using ROC analysis, with PR analysis used to account for class imbalance. Results The cohort included 12 patients (mean age 57.5 ± 18.0 years, 75% male), evenly split between ischemic and non‐ischemic cardiomyopathy. Most patients had an ICD in situ (91.7%) and were receiving beta‐blockers (83.3%), with 58.3% on antiarrhythmic therapy. Baseline clinical and procedural characteristics are summarized in Table S1. Dominant Frequency Feasibility and Distribution DF analysis and projection to the 3D ventricular mesh were successful in all patients. Projection accuracy was high, with mean projection errors ranging from 1.13 to 3.96 mm (Table 1). Median distances were generally < 1.6 mm, with a small number of outliers exceeding 9 mm in two cases. Table 1Number of ablation points per case and corresponding projection errors on the left ventricular mesh.Case IDNumber of ablation points (n)Mean distance (mm)Median distance (mm)Min distance (mm)Max distance (mm)1691.411.240.054.062181.800.920.029.473111.131.200.361.944581.411.230.034.14551.511.630.432.886351.481.080.055.147411.250.820.054.868432.351.400.0310.17943.963.953.084.8510711.180.870.004.4211541.220.810.044.8212221.901.580.035.53 Number of ablation points per case and corresponding projection errors on the left ventricular mesh. Case‐specific DF thresholds ranged from 30 to 400 Hz. Thresholds were lower for SmartTouch recordings (30–160 Hz) and higher for Pentaray recordings (100–400 Hz), consistent with expected differences in electrode size and interelectrode spacing (Figure 3). The number of DF‐positive points per case varied from 252 to 1140, with SmartTouch datasets tending to have fewer DF points than Pentaray datasets. Mesh sizes ranged from 2490 to 11 960 points (Table 2). Inter‐case variability in DF thresholds for SmartTouch and Pentaray catheters. Overview of manually assigned DF thresholds for each patient, stratified by catheter type. SmartTouch catheter recordings generally required lower thresholds (30–160 Hz), whereas Pentaray catheter recordings required higher thresholds (100–400 Hz), reflecting differences in spectral content and signal fidelity. Table 2Manually assigned DF thresholds, total DF point counts by catheter type, and corresponding mesh and operator‐defined ablation point statistics for each VT case.Case IDCath. typeManually assigned threshold (Hz)Total DF points (n)Total ablation points (n)Total mesh points (n)Total non‐ablation points (n)1SmartTouch4025269249024212SmartTouch3081718957195532Pentaray400114018957195533Pentaray10062811403040194Pentaray35093658767376155SmartTouch303505337333685Pentaray4002685337333686SmartTouch16031735428042456Pentaray37027435428042457Pentaray10058141554755068SmartTouch4087749411640679SmartTouch305294848184779Pentaray10094348481847710SmartTouch456257111 96011 88910Pentaray2805117111 96011 88911SmartTouch50318545813575911Pentaray150542545813575912SmartTouch304032273567334 Manually assigned DF thresholds, total DF point counts by catheter type, and corresponding mesh and operator‐defined ablation point statistics for each VT case. Spatial Correspondence and Discriminative Performance (I) Soft Score DF activity showed spatial concordance with operator‐defined ablation targets. Soft recall values were high in nearly all cases (0.776–0.999), indicating close proximity of DF regions to ablation sites. Soft precision values varied more widely (0.025–0.754). The highest soft recall occurred in Case 9 (0.999) and the highest soft precision in Case 11 (0.754). SmartTouch datasets generally achieved higher mean soft recall (~0.89) than Pentaray datasets (~0.86). In all but one case (Case 9, Pentaray), proximity scores at ablation sites were significantly higher than at non‐ablation sites after Bonferroni correction (p = 0.0028; Table 3, Figure 4). Table 3Spatial concordance metrics for DF mapping: proximity scores, soft precision/recall, ROC AUC, average precision, and baseline precision.Case IDCath. typeScore ablation (median ± IQR)Score non‐ablation (median ± IQR) p‐valueSoft precision (0–1)Soft recall (0–1)ROC (AUC) (0–1)AP (PR curve) (0–1)Baseline precision (%)1SmartTouch0.936 ± 0.1960.004 ± 0.193< 0.00280.6250.8080.8630.0912.73%2SmartTouch0.994 ± 0.0220.011 ± 0.459< 0.00280.3190.9390.8970.0100.19%2Pentaray0.994 ± 0.0480.077 ± 0.672< 0.00280.1810.8020.7970.0060.19%3Pentaray0.909 ± 0.1240.020 ± 0.732< 0.00280.0640.8890.8100.0070.27%4Pentaray0.986 ± 0.0270.008 ± 0.481< 0.00280.6230.9680.8710.0280.76%5SmartTouch0.958 ± 0.0670.006 ± 0.386< 0.00280.1770.9490.8840.0070.15%5Pentaray0.958 ± 0.0670.000 ± 0.125< 0.00280.1820.9490.9120.0100.15%6SmartTouch0.957 ± 0.0890.000 ± 0.185< 0.00280.2170.9380.9170.0450.82%6Pentaray0.968 ± 0.0760.000 ± 0.025< 0.00280.4040.9440.9350.0580.82%7Pentaray0.943 ± 0.1590.000 ± 0.140< 0.00280.5290.8130.8620.0250.74%8SmartTouch0.863 ± 0.2230.607 ± 0.774< 0.00280.2210.7760.6220.0151.19%9SmartTouch1.000 ± 0.0010.000 ± 0.131< 0.00280.0980.9990.9380.0050.05%9Pentaray0.998 ± 0.0070.066 ± 0.622> 0.00280.0250.9950.8890.0030.05%10SmartTouch0.985 ± 0.0180.000 ± 0.013< 0.00280.4860.9560.9450.0500.59%10Pentaray0.983 ± 0.0240.000 ± 0.001< 0.00280.5300.9290.9530.0590.59%11SmartTouch0.978 ± 0.1450.000 ± 0.002< 0.00280.7540.8510.9360.0660.93%11Pentaray0.951 ± 0.2560.004 ± 0.307< 0.00280.4690.8230.8710.0340.93%12SmartTouch0.985 ± 0.0330.000 ± 0.058< 0.00280.3150.9520.9390.0240.30% Spatial concordance metrics for DF mapping: proximity scores, soft precision/recall, ROC AUC, average precision, and baseline precision. Proximity of DF activity to operator‐defined ablation sites across all cases. Violin plots showing the distribution of proximity scores at operator‐defined ablation (blue) and non‐ablation (orange) mesh points. Scores range from 0 (far from DF activity) to 1 (directly overlapping DF points). Across cases, ablation sites consistently show higher proximity to DF regions, indicating spatial concordance. Medians and interquartile ranges are indicated within each violin. (II) Discriminative Performance ROC AUC values ranged from 0.622 (Case 8, SmartTouch) to 0.953 (Case 10, Pentaray), reflecting moderate to strong discrimination between ablation and non‐ablation points. Average precision values were low in absolute terms (0.003–0.091) due to class imbalance but exceeded baseline precision in all cases. (III) Catheter Comparison SmartTouch recordings generally produced slightly higher soft recall and greater separation between ablation and non‐ablation scores. For example, in Case 1 (SmartTouch), the median proximity score at ablation sites was 0.936 (IQR 0.196) compared with 0.004 (IQR 0.193) at non‐ablation sites. Case 8 (SmartTouch) showed the least separation and the lowest AUC (0.622). Discussion This study demonstrates that dominant frequency mapping with 3D anatomical integration is feasible in patients undergoing substrate‐guided VT ablation, and that DF activity shows consistent spatial alignment with operator‐defined ablation targets. Across both catheter recordings, high soft recall values were observed in nearly all cases, indicating that most lesions were delivered within close spatial proximity to DF‐positive regions. Moderate‐to‐strong discriminative performance and reproducibility across catheter types suggest technical feasibility when analyzed using case‐specific spectral scaling. Relation to the Current Functional Mapping Landscape The field of VT ablation has moved steadily from purely anatomical approaches toward functional mapping strategies that aim to identify the electrically active components of the substrate [10, 11]. DEEP and EDP mapping apply programmed stimulation to expose conduction slowing, which can reveal diastolic pathways critical to VT maintenance [4, 12, 13]. Early clinical reports suggest that targeting these sites can improve procedural specificity. However, DEEP and EDP mapping require additional pacing protocols, can prolong procedure time, and are dependent on patient haemodynamic stability. They may not be feasible in patients with limited pacing tolerance or in those in whom arrhythmia induction is avoided. DF mapping offers a complementary, stimulus‐independent approach. By extracting spectral features from routine sinus rhythm or paced data, DF analysis can be performed without altering the activation sequence or provoking arrhythmia. This makes it particularly attractive for use in haemodynamically unstable patients or when procedural strategy emphasizes substrate modification without VT induction. Whereas DEEP and EDP identify inducible conduction delay during programmed stimulation, DF captures spectral complexity related to tissue heterogeneity and thus probes a different physiological property. Other stimulus‐independent approaches, such as ILAM, rely on activation‐ and amplitude‐based mapping. Recent work combining coherent mapping with ILAM‐derived deceleration zones has demonstrated spatial convergence of multiple functional substrate markers, supporting the concept of multiparametric functional substrate assessment [14]. In support of this multiparametric concept, Yalin et al. evaluated coherent mapping‐derived slow conduction zones in 32 patients with ischemic cardiomyopathy undergoing VT ablation, comparing SCZs to traditional substrate markers and ILAM‐derived deceleration zones [14]. SCZs were consistently identified adjacent to low‐voltage areas and colocalized with ILAM DZs in 56.3% of cases, with additional overlap with LPs/LAVAs in selected patients. These findings suggest partial spatial convergence across functional markers while also indicating that each approach may capture distinct substrate properties, supporting a multiparametric strategy. Within the broader stimulus‐independent space, frequency‐domain mapping has also been implemented in commercial mapping platforms. In EnSite X, OT Near Field derives a peak‐frequency trace using a wavelet‐based approach that tracks high‐frequency components over time to support near‐field annotation [15]. In scar‐related VT mapping, Tonko et al. reported that near‐field detection localized critical circuit segments in 77.7% of cases relative to manually reviewed VT activation maps, but also observed that peak frequency as a stand‐alone substrate feature did not differentiate VT isthmus sites from low‐voltage bystander sites in their cohort [16]. In a multicentre VT ablation cohort, Mayer et al. evaluated substrate‐based PF mapping against activation‐demarcated isthmus zones and highlighted that wavelet‐derived PF can emphasize low‐amplitude, highly fractionated signals (distinct from Fourier‐derived dominant frequency, which reflects the highest‐energy component), and that mapping context, including rhythm and amiodarone exposure, may influence PF‐based performance [8]. Our approach is conceptually aligned with frequency‐domain mapping, but differs in implementation and output. We compute an FFT‐based DF metric from segmented electrograms and integrate DF‐defined regions as 3D projected substrate volumes within the CARTO environment. Rather than proposing catheter‐invariant absolute thresholds, interpretation emphasizes within‐case spatial patterning using a transparent case‐specific thresholding framework, and we add quantitative spatial concordance metrics to relate DF‐defined regions to procedural targeting. Direct head‐to‐head comparison with platform‐specific PF implementations (and their proprietary near‐field detection pipelines) was outside the scope of the present dataset and remains an important direction for future work. Mechanistic Considerations The mechanistic link between high DF activity and arrhythmogenic substrate likely reflects a combination of factors. Regions of slow conduction or structural discontinuity may generate complex, fractionated electrograms with increased high‐frequency components [17, 18, 19]. Prior experimental work has shown that high PF values can be associated with midmyocardial fibrosis and deep intramural substrate, which are often difficult to detect using bipolar voltage mapping alone [16, 20, 21]. In practice, sites with high PF often correspond to electrograms that appear visually fractionated or contain rapid deflections, whereas sites with low PF show more organized signals (Figure 5). This difference can often be appreciated directly in the raw intracardiac recordings. DF analysis may therefore help to reveal spatial patterns within or adjacent to scar that are not apparent on conventional voltage maps. Representative high‐ versus low‐PF electrograms with corresponding spectra. Example of a high‐PF fractionated electrogram (blue, PF = 42.3 Hz) and a low‐PF organized electrogram (red, PF = 23.9 Hz). Fractionated signals display multiple rapid deflections and higher frequency components, whereas organized signals show smoother morphology with lower PF. These distinctions illustrate a potential mechanistic link between spectral content and arrhythmogenic substrate. The present results support this hypothesis. Soft recall was consistently high, suggesting that DF‐positive regions capture much of the region targeted for ablation, even when voltage or late potential mapping might be less specific. Variation in soft precision likely reflects the broader spatial distribution of DF activity compared with the relatively focal nature of ablation lesions. This could indicate that some DF‐positive areas represent non‐targeted substrate, either because of procedural strategy, anatomical inaccessibility, or substrate located in deeper myocardial layers. Clinical Implications This study introduces a DF mapping workflow that integrates case‐specific spectral thresholding with three‐dimensional anatomy and continuous spatial concordance analysis. After manual region‐of‐interest definition and threshold selection, the analysis is performed using a computational pipeline and is applicable across both single‐tip and multielectrode mapping catheters, with spatial correspondence quantified using continuous proximity metrics rather than binary overlap. This approach enables quantitative evaluation of the spatial relationship between DF‐defined regions and procedural ablation targets using routine mapping data without additional pacing protocols or arrhythmia induction. This may be of interest in contexts where patients are haemodynamically unstable, have diffuse scar, or when procedural strategy emphasizes substrate modification without VT induction. Importantly, DF mapping is not intended as a standalone tool to prospectively define ablation targets, and the observed low soft precision may reflect limited specificity of DF mapping itself, in addition to procedural strategy or deeper myocardial substrate. Because DF mapping captures spectral characteristics rather than pacing‐induced conduction delay, it probes a different physiological property than functional mapping strategies such as DEEP or EDP. It may therefore serve as a complementary component within multimodal mapping workflows that combine spectral, temporal, and structural information. Prospective studies will be required to distinguish between intrinsic limitations in DF specificity, procedural strategy, and deeper myocardial substrate as contributors to low soft precision, and to determine how DF‐defined spatial patterns relate to clinical endpoints and decision‐making. Limitations This study was retrospective, single‐centered, and included a limited number of patients. DF mapping should therefore be interpreted as exploratory. DF thresholds were selected manually from case‐specific frequency histograms by a single analyst in a retrospective manner, which may introduce operator dependency and potential bias. Inter‐operator reproducibility and the robustness of spatial concordance metrics to small variations in threshold selection were not formally assessed. Thresholding was performed in a relative, patient‐specific, and catheter‐dependent manner to account for differences in spectral content. DF mapping is therefore intended as a within‐patient functional marker and is not suitable for absolute or inter‐patient comparison, as cross‐device standardization was not addressed. Spatial concordance analysis relied on operator‐defined ablation sites, which do not represent a functional ground truth for VT circuit and may not capture the full extent of the arrhythmogenic substrate. Procedural data did not consistently distinguish ablation lesions delivered for substrate modification from those targeting critical sites, precluding stratified analysis of precision and recall by ablation type. Because electroanatomic mapping data are spatially autocorrelated due to point proximity and interpolation, ROC‐ and precision‐recall‐based metrics should therefore be interpreted as measures of spatial discrimination rather than diagnostic accuracy and may overestimate apparent performance. Signal‐processing limitations should also be considered. Fractionated electrograms do not always yield high peak frequencies, and PF estimation may be influenced by region‐of‐interest selection, particularly when using short, non‐periodic signals. The absence of spectral windowing may have increased spectral leakage and inflated high‐frequency components. Moreover, defining dominant frequency as a single peak simplifies complex, multi‐component electrograms and may not fully capture spectral heterogeneity, especially when multiple spectral peaks are present. Comparisons with DEEP or EDP mapping were not performed, and long‐term follow‐up data were unavailable, precluding assessment of the prognostic value of DF mapping. Prospective multicentre studies with predefined thresholding strategies are therefore warranted. Conclusion Dominant frequency mapping with three‐dimensional anatomical integration was feasible across different catheter types and showed consistent spatial concordance with operator‐defined ventricular ablation sites. This was achieved using a workflow that combined electrogram segmentation, case‐specific spectral thresholding, and mesh‐based projection. The approach is stimulus‐independent, can be applied to routine mapping data, and can be explored in relation to established pacing‐based mapping strategies. DF values should be interpreted as case‐specific and are not directly comparable across patients, catheter types, or institutions. Prospective multicentre studies are warranted to determine its potential clinical relevance in relation to functional substrate and clinical outcomes. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Supporting File Acknowledgments This work was supported by an EHRA Training Fellowship Grant to Dr Bhagirath. The research was also supported by an Academy Van Leersum grant of the Academy Medical Sciences Fund (Royal Netherlands Academy of Arts and Sciences), Netherlands Heart Institute Fellowship, CVON PREDICT2 Young Talent Program, and NIHR Biomedical Research Centre and CRF at Guy's and St Thomas' NHS Foundation Trust and King's College London. Dr Postema was supported by the Dutch Heart Foundation grant 03‐003‐2021‐T061. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Supplementary Materials Supporting File Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.